Jeremiah Anthony Wala, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Genomic Structural Variation | 3 | 2020 | 63 | 0.820 |
Why?
|
INDEL Mutation | 3 | 2020 | 266 | 0.760 |
Why?
|
Radiotherapy, Intensity-Modulated | 3 | 2013 | 801 | 0.600 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 4 | 2013 | 1660 | 0.560 |
Why?
|
Genome, Human | 6 | 2020 | 4417 | 0.520 |
Why?
|
Genomics | 7 | 2021 | 5794 | 0.520 |
Why?
|
Software | 4 | 2018 | 4419 | 0.500 |
Why?
|
Sequence Deletion | 2 | 2018 | 1493 | 0.500 |
Why?
|
Proto-Oncogenes | 1 | 2016 | 320 | 0.500 |
Why?
|
Immunotherapy, Adoptive | 1 | 2023 | 1454 | 0.440 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2016 | 646 | 0.410 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 381 | 0.400 |
Why?
|
High-Throughput Nucleotide Sequencing | 5 | 2018 | 3616 | 0.370 |
Why?
|
Translocation, Genetic | 1 | 2016 | 1388 | 0.350 |
Why?
|
Sequence Analysis, DNA | 3 | 2020 | 4713 | 0.350 |
Why?
|
Carcinoma, Medullary | 2 | 2021 | 115 | 0.340 |
Why?
|
Chromosome Aberrations | 1 | 2016 | 1764 | 0.330 |
Why?
|
Prostatic Neoplasms | 3 | 2023 | 11345 | 0.270 |
Why?
|
Gene Rearrangement | 6 | 2020 | 1122 | 0.260 |
Why?
|
Neoplasms | 8 | 2023 | 22072 | 0.250 |
Why?
|
Computational Biology | 2 | 2021 | 3505 | 0.250 |
Why?
|
Germ-Line Mutation | 2 | 2021 | 1841 | 0.210 |
Why?
|
Retroelements | 1 | 2020 | 163 | 0.160 |
Why?
|
Long Interspersed Nucleotide Elements | 1 | 2020 | 330 | 0.150 |
Why?
|
Databases, Genetic | 3 | 2021 | 1738 | 0.150 |
Why?
|
Haplotypes | 2 | 2021 | 2764 | 0.150 |
Why?
|
Oncogene Proteins v-myb | 1 | 2016 | 25 | 0.130 |
Why?
|
Mutation | 9 | 2022 | 29932 | 0.130 |
Why?
|
Virus Integration | 1 | 2018 | 302 | 0.130 |
Why?
|
Androgens | 1 | 2023 | 1291 | 0.130 |
Why?
|
Endometrial Hyperplasia | 1 | 2016 | 97 | 0.130 |
Why?
|
DNA Copy Number Variations | 4 | 2020 | 2013 | 0.120 |
Why?
|
Abdominal Neoplasms | 1 | 2016 | 286 | 0.120 |
Why?
|
Glioma | 2 | 2022 | 3420 | 0.120 |
Why?
|
Pelvic Neoplasms | 1 | 2016 | 248 | 0.120 |
Why?
|
Androgen Antagonists | 1 | 2023 | 1442 | 0.120 |
Why?
|
Chromosomes | 1 | 2017 | 575 | 0.110 |
Why?
|
Kidney Neoplasms | 2 | 2021 | 4312 | 0.110 |
Why?
|
Alleles | 2 | 2021 | 6898 | 0.110 |
Why?
|
Sequence Alignment | 1 | 2017 | 2176 | 0.100 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2019 | 1313 | 0.100 |
Why?
|
Drug Synergism | 1 | 2016 | 1754 | 0.100 |
Why?
|
Oncogene Proteins, Fusion | 2 | 2021 | 1596 | 0.100 |
Why?
|
Receptors, Androgen | 1 | 2018 | 1077 | 0.100 |
Why?
|
Radiotherapy Dosage | 3 | 2013 | 2897 | 0.100 |
Why?
|
DNA Breaks | 2 | 2021 | 47 | 0.090 |
Why?
|
Tumor Microenvironment | 1 | 2023 | 3844 | 0.090 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 11712 | 0.080 |
Why?
|
Humans | 24 | 2023 | 760621 | 0.080 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2018 | 1403 | 0.080 |
Why?
|
Evolution, Molecular | 1 | 2016 | 1885 | 0.070 |
Why?
|
Clinical Trials as Topic | 1 | 2023 | 8056 | 0.070 |
Why?
|
RNA-Binding Proteins | 1 | 2016 | 1894 | 0.070 |
Why?
|
Endometrial Neoplasms | 1 | 2016 | 1357 | 0.070 |
Why?
|
Radiometry | 1 | 2012 | 813 | 0.070 |
Why?
|
T-Lymphocytes | 1 | 2023 | 10181 | 0.060 |
Why?
|
Genetic Variation | 1 | 2020 | 6551 | 0.060 |
Why?
|
Radiation Dosage | 1 | 2012 | 1958 | 0.060 |
Why?
|
Genetic Heterogeneity | 2 | 2018 | 724 | 0.060 |
Why?
|
Cell Line, Tumor | 4 | 2021 | 16939 | 0.050 |
Why?
|
Brain Neoplasms | 1 | 2022 | 8986 | 0.050 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2016 | 4024 | 0.040 |
Why?
|
Diploidy | 1 | 2020 | 132 | 0.040 |
Why?
|
Chromosome Inversion | 1 | 2020 | 120 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2021 | 8515 | 0.040 |
Why?
|
Adenocarcinoma | 1 | 2016 | 6315 | 0.040 |
Why?
|
Genetic Association Studies | 2 | 2021 | 2717 | 0.040 |
Why?
|
Male | 6 | 2023 | 359744 | 0.040 |
Why?
|
Molecular Sequence Annotation | 1 | 2020 | 524 | 0.040 |
Why?
|
Mutagenesis, Insertional | 1 | 2020 | 652 | 0.040 |
Why?
|
Gene Duplication | 1 | 2018 | 313 | 0.040 |
Why?
|
Genes, myc | 1 | 2018 | 395 | 0.040 |
Why?
|
raf Kinases | 1 | 2016 | 118 | 0.030 |
Why?
|
Genes, Neoplasm | 1 | 2018 | 370 | 0.030 |
Why?
|
Models, Biological | 1 | 2012 | 9467 | 0.030 |
Why?
|
Anilides | 1 | 2018 | 409 | 0.030 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2016 | 256 | 0.030 |
Why?
|
Neoplasm Transplantation | 1 | 2019 | 2014 | 0.030 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2018 | 656 | 0.030 |
Why?
|
Telomerase | 1 | 2020 | 746 | 0.030 |
Why?
|
Comparative Genomic Hybridization | 1 | 2016 | 473 | 0.030 |
Why?
|
Ubiquitin | 1 | 2019 | 838 | 0.030 |
Why?
|
Ploidies | 1 | 2013 | 275 | 0.030 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2019 | 2506 | 0.030 |
Why?
|
Mice, Nude | 1 | 2019 | 3607 | 0.030 |
Why?
|
PTEN Phosphohydrolase | 1 | 2018 | 1115 | 0.030 |
Why?
|
Histones | 1 | 2022 | 2583 | 0.020 |
Why?
|
Lung Neoplasms | 1 | 2016 | 13262 | 0.020 |
Why?
|
Enhancer Elements, Genetic | 1 | 2018 | 1356 | 0.020 |
Why?
|
Algorithms | 1 | 2012 | 13981 | 0.020 |
Why?
|
Sequence Analysis, RNA | 1 | 2019 | 2005 | 0.020 |
Why?
|
Cell Cycle Proteins | 1 | 2022 | 3446 | 0.020 |
Why?
|
Time Factors | 1 | 2012 | 40165 | 0.020 |
Why?
|
Cell Cycle | 1 | 2019 | 2934 | 0.020 |
Why?
|
RNA Interference | 1 | 2019 | 2846 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2022 | 4490 | 0.020 |
Why?
|
Mutagenesis | 1 | 2013 | 1234 | 0.020 |
Why?
|
Phylogeny | 1 | 2016 | 2775 | 0.020 |
Why?
|
Genetic Loci | 1 | 2018 | 2618 | 0.020 |
Why?
|
Prostate-Specific Antigen | 1 | 2018 | 2529 | 0.020 |
Why?
|
Antigens, Neoplasm | 1 | 2016 | 1998 | 0.020 |
Why?
|
Child | 3 | 2022 | 79806 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2018 | 4902 | 0.020 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2016 | 2058 | 0.020 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2016 | 2864 | 0.020 |
Why?
|
Genotype | 1 | 2021 | 12960 | 0.020 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2016 | 2053 | 0.020 |
Why?
|
Pyridines | 1 | 2018 | 2879 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 2 | 2021 | 17790 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2013 | 1741 | 0.020 |
Why?
|
Recurrence | 1 | 2016 | 8482 | 0.010 |
Why?
|
Kidney | 1 | 2019 | 7064 | 0.010 |
Why?
|
Protein Kinase Inhibitors | 1 | 2018 | 5643 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2021 | 15789 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2020 | 12626 | 0.010 |
Why?
|
Phenotype | 1 | 2018 | 16546 | 0.010 |
Why?
|
Epigenesis, Genetic | 1 | 2013 | 3758 | 0.010 |
Why?
|
Disease Progression | 1 | 2016 | 13502 | 0.010 |
Why?
|
Child, Preschool | 1 | 2021 | 42063 | 0.010 |
Why?
|
Computer Simulation | 1 | 2012 | 6218 | 0.010 |
Why?
|
Female | 3 | 2021 | 391270 | 0.010 |
Why?
|
Pancreatic Neoplasms | 1 | 2012 | 5351 | 0.010 |
Why?
|
Signal Transduction | 1 | 2016 | 23376 | 0.010 |
Why?
|
Mice | 1 | 2019 | 81208 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2018 | 65017 | 0.010 |
Why?
|
Animals | 1 | 2019 | 167963 | 0.000 |
Why?
|
Aged | 1 | 2018 | 169152 | 0.000 |
Why?
|
Middle Aged | 1 | 2018 | 220352 | 0.000 |
Why?
|